Orthovanadate de Sodium g 1 pc x 5 g

Non disponible en dehors du Royaume-Uni et de l'Irlande

Biochem/physiol Actions

Cell permeable: no

Reversible: no

Product does not compete with ATP.

Primary TargetNa⁺,K⁺-ATPase, acid , alkaline phosphatases, phosphofructokinase, and adenylate kinase

General description

A broad spectrum potent inhibitor of protein tyrosine phosphatases. Also known to inhibit Na⁺/K⁺ ATPase, acid and alkaline phosphatases, phosphofructokinase, and adenylate kinase. Most recently shown to inhibit ATPase activity of the reconstituted binding protein-dependent ATP-Binding Cassette (ABC) transporter for maltose (MalFGK₂) of Salmonella typhimurium in the micromolar range. Can be converted to pervanadate by hydrogen peroxide.

A broad spectrum potent inhibitor of protein tyrosine phosphatases. Also known to inhibit Na⁺,K⁺-ATPase, acid and alkaline phosphatases, phosphofructokinase, and adenylate kinase. Also inhibits the ATPase activity of the reconstituted binding protein-dependent ATP-Binding Cassette (ABC) transporter for maltose (MalFGK₂) of Salmonella typhimurium in the micromolar range. Can be converted to pervanadate by hydrogen peroxide.

Legal Information

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

Other Notes

Huyer, G., et al. 1997. J. Biol. Chem. 272, 843.Hunke, S., et al. 1995. Biochem. Biophys. Res. Commun.216, 589.Levchuck, S.G., et al. 1994. Pediatric Res.37, 382A.Fohr, K.J., et al. 1989. Biochem. J.262, 83.Swarup, G., et al. 1982. Biochem. Biophys. Res. Commun.107, 1104.Seargeant, L.E. and Stinson, R.A. 1979. Biochem. J.181, 247.

Packaging

5 g in Plastic ampoule

Reconstitution

Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.

Warning

Toxicity: Harmful (C)